SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
PHARMA: Company May Seek Partnership During Final Trials
A small and low-key drugmaker in Coronado is making an eye drop product that may replace reading glasses.
BIOTECH: NuVasive’s Lucier Sets Cadence for Co.’s March Toward Its Goals
Greg Lucier ranks high on my list of San Diego bigwigs, but the biotech executive has largely eluded me for the past two years.
San Diego’s Abreos Biosciences has raised $725,000 in a seed round of funding.
San Diego’s Oncternal Therapeutics Inc. has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration for its pediatric cancer drug candidate.
BioSurplus Inc., a local company that buys and sells pre-owned lab equipment, has appointed Bill VanDeWeghe as its new president and chief executive officer.
CASIS, the organization that manages the U.S. national lab on the International Space Station, is setting up a permanent office in San Diego, Mayor Keven Faulconer announced on July 12.
Trovagene Inc., a local firm that makes liquid biopsy tests, is collaborating with the University of Southern California’s Norris Comprehensive Cancer Center on the best way to use its tests in the clinic, the company announced Tuesday.
Coronado-based Presbyopia Therapies LLC has raised nearly $4 million in equity financing, according to a recent form filed with the Securities and Exchange Commission.
Sorrento Therapeutics Inc., a local biopharmaceutical company, has landed a partnership with French pharmaceutical giant Servier to develop products based on Sorrento’s tech.
Illumina Inc. has settled a patent-infringement lawsuit with New York-based Enzo Biochem subsidiary Enzo Life Sciences for $21 million, according to several wire services.
Two major bond credit rating services have weighed in on the fiscal health of Palomar Health, the public hospital district announced.
From the polio vaccine to the MRI scanner, America has a rich history of developing lifesaving medicines. The Trans-Pacific Partnership (TPP) trade agreement is important to small pharmaceutical companies like mine and our ability to bring the next generation of medicines to the global marketplace.
It’s tough times for Regulus Therapeutics Inc. Once a local biotech heavyweight valued at nearly $1 billion, the San Diego company’s shares have fallen dramatically over the last 18 months. The company’s valuation is hovering around $170 million after the latest blow: a FDA-ordered suspension on Regulus’ lead product candidate, RG-101.
BIOTECH: Halozyme Gets Creative in Pursuit of Cash
In today’s market, with valuations down and investors wary, it’s critical for biotechs to get creative when looking for cash to fuel research.
Germany-based Curetis GmbH has opened a North American subsidiary in San Diego and named Christopher M. Bernard as its leader.